196 related articles for article (PubMed ID: 35439787)
1. Implementation of long-acting antiretroviral therapy in low-income and middle-income countries.
Cresswell FV; Lamorde M
Curr Opin HIV AIDS; 2022 May; 17(3):127-134. PubMed ID: 35439787
[TBL] [Abstract][Full Text] [Related]
2. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
3. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
[TBL] [Abstract][Full Text] [Related]
4. Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Patel P; Teichner P; Elliot E; Boffito M; Murray M; Polli JW; Baker M; Ford SL; Han K; Russu A; Crauwels H; D'Amico RD; Spreen WR; van Wyk J
Ther Adv Infect Dis; 2023; 10():20499361231214626. PubMed ID: 38107552
[TBL] [Abstract][Full Text] [Related]
5. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection.
Chounta V; Snedecor SJ; Wu S; Van de Velde N
BMC Infect Dis; 2022 May; 22(1):428. PubMed ID: 35508986
[TBL] [Abstract][Full Text] [Related]
6. Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Overton ET; Richmond G; Rizzardini G; Thalme A; Girard PM; Wong A; Porteiro N; Swindells S; Reynes J; Noe S; Harrington C; Español CM; Acuipil C; Aksar A; Wang Y; Ford SL; Crauwels H; van Eygen V; Van Solingen-Ristea R; Latham CL; Thiagarajah S; D'Amico R; Smith KY; Vandermeulen K; Spreen WR
Clin Infect Dis; 2023 May; 76(9):1646-1654. PubMed ID: 36660819
[TBL] [Abstract][Full Text] [Related]
7. Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy.
Mills A; Richmond GJ; Newman C; Osiyemi O; Cade J; Brinson C; De Vente J; Margolis DA; Sutton KC; Wilches V; Hatch S; Roberts J; McCoig C; Garris C; Vandermeulen K; Spreen WR
AIDS; 2022 Feb; 36(2):195-203. PubMed ID: 34652287
[TBL] [Abstract][Full Text] [Related]
8. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Margolis DA; Gonzalez-Garcia J; Stellbrink HJ; Eron JJ; Yazdanpanah Y; Podzamczer D; Lutz T; Angel JB; Richmond GJ; Clotet B; Gutierrez F; Sloan L; Clair MS; Murray M; Ford SL; Mrus J; Patel P; Crauwels H; Griffith SK; Sutton KC; Dorey D; Smith KY; Williams PE; Spreen WR
Lancet; 2017 Sep; 390(10101):1499-1510. PubMed ID: 28750935
[TBL] [Abstract][Full Text] [Related]
9. Realizing the promise of long-acting antiretroviral treatment strategies for individuals with HIV and adherence challenges: an illustrative case series.
Kilcrease C; Yusuf H; Park J; Powell A; Rn LJ; Rn JO; Lmsw BD; Weld ED; Dooley KE; Arrington-Sanders R; Agwu AL
AIDS Res Ther; 2022 Nov; 19(1):56. PubMed ID: 36435793
[TBL] [Abstract][Full Text] [Related]
10. Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort.
Sension MG; Brunet L; Hsu RK; Fusco JS; Cochran Q; Uranaka C; Sridhar G; Vannappagari V; Van Wyk J; McCurdy L; Wohlfeiler MB; Fusco GP
Infect Dis Ther; 2023 Dec; 12(12):2807-2817. PubMed ID: 37966701
[TBL] [Abstract][Full Text] [Related]
11. Cabotegravir-Rilpivirine: The First Complete Long-Acting Injectable Regimen for the Treatment of HIV-1 Infection.
Durham SH; Chahine EB
Ann Pharmacother; 2021 Nov; 55(11):1397-1409. PubMed ID: 33593093
[TBL] [Abstract][Full Text] [Related]
12. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
Rizzardini G; Overton ET; Orkin C; Swindells S; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Girard PM; Oka S; Andrade-Villanueva JF; Richmond GJ; Baumgarten A; Masiá M; Latiff G; Griffith S; Harrington CM; Hudson KJ; St Clair M; Talarico CL; Patel P; Cutrell A; Van Eygen V; D'Amico R; Mrus JM; Wu S; Ford SL; Chow K; Roberts J; Wills A; Walters N; Vanveggel S; Van Solingen-Ristea R; Crauwels H; Smith KY; Spreen WR; Margolis DA
J Acquir Immune Defic Syndr; 2020 Dec; 85(4):498-506. PubMed ID: 33136751
[TBL] [Abstract][Full Text] [Related]
13. Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain.
Moreno S; Rivero A; Ventayol P; Falcó V; Torralba M; Schroeder M; Neches V; Vallejo-Aparicio LA; Mackenzie I; Turner M; Harrison C
Infect Dis Ther; 2023 Aug; 12(8):2039-2055. PubMed ID: 37452174
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis.
Wang W; Zhao S; Wu Y; Duan W; Li S; Li Z; Guo C; Wang W; Zhang T; Wu H; Huang X
JMIR Public Health Surveill; 2023 Jul; 9():e46767. PubMed ID: 37498645
[TBL] [Abstract][Full Text] [Related]
15. Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
Orkin C; Bernal Morell E; Tan DHS; Katner H; Stellbrink HJ; Belonosova E; DeMoor R; Griffith S; Thiagarajah S; Van Solingen-Ristea R; Ford SL; Crauwels H; Patel P; Cutrell A; Smith KY; Vandermeulen K; Birmingham E; St Clair M; Spreen WR; D'Amico R
Lancet HIV; 2021 Nov; 8(11):e668-e678. PubMed ID: 34656207
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.
Parker B; Ward T; Hayward O; Jacob I; Arthurs E; Becker D; Anderson SJ; Chounta V; Van de Velde N
PLoS One; 2021; 16(2):e0245955. PubMed ID: 33529201
[TBL] [Abstract][Full Text] [Related]
17. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Overton ET; Richmond G; Rizzardini G; Jaeger H; Orrell C; Nagimova F; Bredeek F; García Deltoro M; Swindells S; Andrade-Villanueva JF; Wong A; Khuong-Josses MA; Van Solingen-Ristea R; van Eygen V; Crauwels H; Ford S; Talarico C; Benn P; Wang Y; Hudson KJ; Chounta V; Cutrell A; Patel P; Shaefer M; Margolis DA; Smith KY; Vanveggel S; Spreen W
Lancet; 2021 Dec; 396(10267):1994-2005. PubMed ID: 33308425
[TBL] [Abstract][Full Text] [Related]
18. Clinical implementation of long-acting antiretroviral treatment in high-income countries: challenges and advantages.
Waters L; Sparrowhawk A
Curr Opin HIV AIDS; 2022 May; 17(3):121-126. PubMed ID: 35439786
[TBL] [Abstract][Full Text] [Related]
19. Frequency of genotypic factors possibly associated with cabotegravir/rilpivirine failure in antiretroviral treatment-naïve and -experienced HIV-1- infected population.
Scheibe K; Urbańska A; Serwin K; Parczewski M
Infect Genet Evol; 2022 Oct; 104():105358. PubMed ID: 36057423
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic.
Howe ZW; Norman S; Lueken AF; Huesgen E; Farmer EK; Jarrell K; Mathis JE; Bonham KW; Hahn J
Pharmacotherapy; 2021 Aug; 41(8):686-699. PubMed ID: 34130357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
